CD33 and acute myeloid leukemia: For example, targeting CD33 on AML cells using gemtuzumab ozogamicin showed remission in AML patients, while serious side effects such as severe myelosuppression and tumor lysis syndrome limited its use in clinical practice (Feldman et al., 2005).